je.st
news
Tag: pivotal
Mercks Investigational Once-Daily Formulation of ISENTRESS (raltegravir) Meets Primary and Secondary Endpoints in Pivotal Phase 3 Study
2016-02-22 14:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Results to be Presented at Future Medical Meeting, and Regulatory Submissions Planned for 2016 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced top-line results from the companys Phase 3 pivotal trial, ONCEMRK. ONCEMRK is evaluating an investigational once-daily formulation of ISENTRESS (raltegravir), known as raltegravir 600 mg (to be given as 2 x 600 mg once-daily), for previously untreated HIV-1 infected adults. Language: English Contact: For MerckMedia:Pamela Eisele, 267-305-3558orCarmen de Gourville, 267-305-4195orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: study
primary
phase
secondary
Stores becoming "pivotal" for purchase returns
2016-02-11 15:29:00| Daily apparel & textile news and comment - from just-style.com
While in-store purchases have dropped, the store remains pivotal when it comes to returns, new research suggests.
Tags: purchase
stores
returns
pivotal
Ford and Pivotal collaborate on software platform for FordPass
2016-02-08 14:56:09| Green Car Congress
Tags: software
ford
platform
collaborate
Merck Completes Enrollment in Pivotal Phase 3 EPOCH Trial Investigating the Efficacy and Safety of Verubecestat in Patients with Mild-to-Moderate Alzheimers Disease
2016-01-28 14:00:26| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. APECS Study Investigating Verubecestat in Patients with Prodromal Alzheimers Ongoing KENILWORTH, N.J. -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today confirmed the completion of enrollment for the EPOCH trial, a Phase 2/3 randomized, placebo-controlled, parallel-group, double-blind study of verubecestat, formerly known as MK-8931, the companys investigational oral small molecule selective beta secretase (BACE1) inhibitor, in patients with mild-to-moderate Alzheimers disease (AD). The ongoing study commenced in November 2012, completed enrollment in the fourth quarter of 2015 and is estimated to reach primary trial completion in July 2017. Language: English read more
Pivotal Research Lowers Whole Foods Market, Inc. (WFM) Price Target to $20.00
2016-01-03 21:15:29| Grocery - Topix.net
The firm presently has a "sell" rating on the stock. Pivotal Research's price target would suggest a potential downside of 40.30% from the stock's previous close.
Tags: price
research
market
target
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] next »